March 16, 2023
5 min watch
Save
VIDEO: FORMULA-509 probes salvage radiation and gonadotropin-releasing hormone regimen
In this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Cancer Institute, discusses the FORMULA-509 trial he co-presented at ASCO Genitourinary Cancers Symposium.
The study examined patients with a rising PSA after radical prostatectomy who had at least one unfavorable risk factor, and who received salvage radiation and 6 months of a gonadotropin-releasing hormone agonist.
“What I think we can say now is for a patient today, using the FORMULA-509 regimen is a very attractive alternative to having to lengthen the duration of hormone therapy to 24 months,” Nguyen said.
Reference:
- Nguyen P, et al. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). Presented at: ASCO Genitourinary Cancers Symposium; ; Feb. 16-18, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Nguyen reports consulting for Bayer, Blue Earth Diagnostics, Boston Scientific, Janssen Oncology and Myovant Sciences; and receiving research funding from Astellas Pharma, Bayer and Janssen.
Read more about